Comparison of clinical outcomes of patients treated with Cre8TM versus Resolute Onyx™ stent

Document Type : Original Article


1 Interventional Cardiologist, Cardiovascular Research Center, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran

2 Fellowship of interventional Cardiology, Tabriz University of Medical Science, Tabriz, Iran

3 PHD, Islamic Azad University, Tehran north branch, Tehran, Iran.

4 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


Introduction: This study aims to compare the clinical outcomes of patients treated with Cre8TM versus Resolute Onyx™ stent.
Material and Methods: In this retrospective study, all patients who underwent Stenting in the catheterization department of ShahidMadani Hospital between 2015 and 2018, were included. Angiographic and angioplasty findings were recorded. The primary end point, which includes total mortality, myocardial infarction, revascularization (adverse events) were recorded.
Results: The mortality rates were similar in both groups. Moreover the myocardial infarction and repeated revascularization did not differ in both groups (p>0.05).The rates of adverse events wasn't   significantly different between the two groups.
Conclusion: Our study showed that efficacy and safety of Cre8™ stents is non-inferior to the Resolute Onyx™ stent.


1.             Bhatia SK. Coronary artery disease.  Biomaterials for Clinical Applications: Springer; 2010. p. 23-49.
2.             Ebrahimi M, Kazemi-Bajestani S, Ghayour-Mobarhan M, Ferns G. Coronary artery disease and its risk factors status in Iran: a review. Iranian Red Crescent Medical Journal. 2011;13(9):610.
3.             Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine. 2004;350(3):221-31.
4.             Holmes Jr DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109(5):634-40.
5.             Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104(17):2007-11.
6.             Van Belle E, Ketelers Rg, Bauters C, Périé M, Abolmaali K, Richard F, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation. 2001;103(9):1218-24.
7.             Moretti C, Lolli V, Perona G, Vignolini M-C, Cabiale K, Falzone M, et al. Cre8™ coronary stent: preclinical in vivo assessment of a new generation polymer-free DES with Amphilimus™ formulation. EuroIntervention. 2012;7(9):1087-94.
8.             Chamani J. Energetic domains analysis of bovine α-lactalbumin upon interaction with copper and dodecyl trimethylammonium bromide. Journal of Molecular Structure. 2010;979(1-3):227-234.
9.             Rothman M. Resolute zotarolimus eluting stent for treatment of long coronary lesions. indian heart journal. 2015;67(3):194.
10.          Kim Y, Oh SS, Jeong MH, Ahn Y, Kim JH, Hong YJ, et al. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: results from the Korea Acute Myocardial infarction Registry (KAMIR). Cardiology journal. 2019;26(5):469-76.
11.          Prati F, Romagnoli E, Valgimigli M, Burzotta F, De Benedictis M, Ramondo A, et al. Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. International journal of cardiology. 2014;176(3):904-9.
12.          Carrié D, Berland J, Verheye S, Hauptmann KE, Vrolix M, Violini R, et al. A multicenter randomized trial comparing amphilimus-with paclitaxel-eluting stents in de novo native coronary artery lesions. Journal of the American College of Cardiology. 2012;59(15):1371-6.
13.          Konigstein M, Banai S, Herz I, Bazan S, Revivo M, Halkin A, et al. Polymer-free drug-eluting stent in unselected patient population: a single center experience. Cardiovascular Revascularization Medicine. 2014;15(6-7):350-3.
14.          Danesh N, Navaee Sedighi Z, Beigoli S, Sharifi-Rad A, Saberi MR, Chamani J. Determining the binding site and binding affinity of estradiol to human serum albumin and holo-transferrin: fluorescence spectroscopic, isothermal titration calorimetry and molecular. Journal of Biomolecular Structure & Dynamics. 2018;37(7):1747-1763.
15.          Romaguera R, Gómez-Hospital JA, Gomez-Lara J, Brugaletta S, Pinar E, Jiménez-Quevedo P, et al. A randomized comparison of reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus: the RESERVOIR clinical trial. JACC: Cardiovascular Interventions. 2016;9(1):42-50.